Document Detail


Just taller or more bone? The impact of growth hormone on osteogenesis imperfecta and idiopathic juvenile osteoporosis.
MedLine Citation:
PMID:  11086654     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There are scant data to date on the use of GH therapy in osteogenesis imperfecta (OI) or in idiopathic juvenile osteoporosis (IJO). In OI, we review three clinical trials (aggregate study population 46), and 13 patient reports from the NCGS, and two independent patient reports. Based on evidence of increased growth rate versus some reported increased fracture rate, we conclude that GH should probably not be used as first-line therapy in OI, pending further data from clinical trials. There are no published reports of the use of GH therapy in IJO and only one patient with documented IJO enrolled in the NCGS. Since IJO presents in the immediate prepubertal period and appears to improve naturally during puberty, it is difficult to differentiate the effects of GH therapy from those of puberty; therefore, we conclude that GH in IJO should currently be used only for research and not in clinical practice.
Authors:
N M Wright
Related Documents :
12916564 - Cerebral histoplasmosis in the azole era: report of four cases and review.
21320614 - Osteoarthritis year 2010 in review: biochemical markers.
3233864 - Myoclonic activity associated with cefmetazole, with a review of neurotoxicity of cepha...
22624994 - The relationship between urban environment and the inflammatory bowel diseases: a syste...
16333924 - Active case finding of tuberculosis: historical perspective and future prospects.
12143924 - Familial erythrophagocytic lymphohistiocytosis (farquhar's disease): involvement of the...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of pediatric endocrinology & metabolism : JPEM     Volume:  13 Suppl 2     ISSN:  0334-018X     ISO Abbreviation:  J. Pediatr. Endocrinol. Metab.     Publication Date:  2000 Sep 
Date Detail:
Created Date:  2001-02-05     Completed Date:  2001-02-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9508900     Medline TA:  J Pediatr Endocrinol Metab     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  999-1002     Citation Subset:  IM    
Affiliation:
Department of Pediatric Endocrinology, Tallahassee Memorial Hospital, FL 32308, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Age of Onset
Body Height*
Child
Clinical Trials as Topic
Growth Hormone / therapeutic use*
Humans
Osteogenesis Imperfecta / drug therapy*
Osteoporosis / drug therapy*
Chemical
Reg. No./Substance:
9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Growth hormone and hypophosphatemic rickets.
Next Document:  Effects of growth hormone on adipose tissue.